Tolterodine
- Generic Name
- Tolterodine
- Brand Names
- Detrol, Detrusitol
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31NO
- CAS Number
- 124937-51-5
- Unique Ingredient Identifier
- WHE7A56U7K
- Background
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
- Indication
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
- Associated Conditions
- Urinary Urge Incontinence
- Associated Therapies
- -
SSR240600C Treatment in Women With Overactive Bladder
- Conditions
- Interventions
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 345
- Registration Number
- NCT00564226
- Locations
- 🇺🇸
Sanofi-Aventis Aministrative Office, Bridgewater, New Jersey, United States
🇵🇹Sanofi-Aventis Administrative Office, Porto Salvo, Portugal
Pharmacological vs Surgical Treatment for Mixed Incontinence
- Conditions
- Interventions
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Imperial College London
- Registration Number
- NCT00523068
- Locations
- 🇬🇧
Demetri C Panayi, London, United Kingdom
Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
- Conditions
- Interventions
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2021-01-27
- Target Recruit Count
- 28
- Registration Number
- NCT00481728
- Locations
- 🇨🇭
Pfizer Investigational Site, Zurich, Switzerland
Overactive Bladder Innovative Therapy Trial (OrBIT)
- Conditions
- Interventions
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- Uroplasty, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00448175
- Locations
- 🇺🇸
Uroplasty, Inc, Minnetonka, Minnesota, United States
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
- Conditions
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1712
- Registration Number
- NCT00444925
- Locations
- 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
- Conditions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2007-08-08
- Lead Sponsor
- elbion AG
- Target Recruit Count
- 275
- Registration Number
- NCT00439192
- Locations
- 🇸🇪
Danderyds Hospital, Stockholm, Sweden
🇸🇪University Hospital Uppsala, Uppsala, Sweden
🇸🇪Karolinska University Hospital Huddinge, Stockholm, Sweden
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 162
- Registration Number
- NCT00413790
- Locations
- 🇺🇸
Investigative Site, Dallas, Texas, United States
A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
- Conditions
- Interventions
- First Posted Date
- 2006-08-25
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 246
- Registration Number
- NCT00368706
Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects
- Conditions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT00332137
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT00323635
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.